CARL · CIK 1794546
What Carlsmed, Inc. told the SEC could break it.
Carlsmed's business rests almost entirely on a single product: it expects its aprevo interbody implants to account for all of its revenue for the foreseeable future, so its results hinge on continued adoption of that one platform. The economics of that product depend heavily on government reimbursement — about 57% of its payor mix is Medicare and Medicare Advantage, and because private payors often follow Medicare's rates, any cut or unfavorable CMS coding would reduce demand, while growth also requires ongoing FDA clearances. Two execution dependencies round out the register: it relies on independent sales agents it does not employ to generate revenue, and on a limited number of U.S. contract manufacturers to 3D-print, sterilize, package and distribute its titanium implants.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- single-product dependence — aprevo interbody implants are all revenuehigh
Carlsmed expects revenue from aprevo interbody implants to account for all of its revenue for the foreseeable future, so its results hinge entirely on continued market acceptance and adoption of the aprevo Technology Platform.
“We expect that revenue from sales of aprevo interbody implants will continue to account for all of our revenue for the foreseeable future.”
SEC filing →As of 2026 - reliance on independent sales agents to generate revenuemedium
Carlsmed relies on independent sales agents (alongside its direct sales team) to promote the aprevo platform and generate sales, subjecting revenue to risks tied to agents it does not employ or fully control.
“We rely on our independent sales agents to generate revenue, which subjects us to various risks.”
SEC filing →As of 2026
Regulatory & policy
- Medicare reimbursement dependence (57% payor mix); CMS DRG/NTAP codes and FDA clearancehigh
About 57% of Carlsmed's payor mix is Medicare/Medicare Advantage and private payors often follow Medicare rates, so reimbursement cuts (or unfavorable CMS DRG/NTAP coding) would reduce demand; growth also depends on FDA clearances like its December 2025 cervical-plating 510(k).
“we estimate that our payor mix was approximately 43% commercial insurance and 57% Medicare and Medicare Advantage insurance. Medicaid and private payors often follow Medicare payment limitations in setting their own reimbursement rates, and any reduction in Medicare reimbursement may result in a similar reduction in payments from private payors, which may result in reduced demand for our products.”
SEC filing →As of 2026
Supplier concentration
- reliance on a limited number of CMOs for manufacture, sterilization, packaging and distributionmedium
Carlsmed relies on a limited number of contract manufacturers (all US-based) to 3D-print, treat, sterilize, package and distribute its titanium aprevo implants, increasing the risk of insufficient quantities, higher cost and reduced control.
“We rely on a limited number of CMOs for the manufacture, treatment, sterilization, packaging, and distribution of our products. This reliance on third parties increases the risk that we will not have sufficient quantities of our products or such quantities at an acceptable cost and reduces our control”
SEC filing →As of 2026
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch